Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DOD Biotech PCLBKK:DOD 67 EV-to-EBITDA is 9.05 as of Sep. 06, 2026, which is 20% below its 10-year median of 11.36. GuruFocus rates BKK:DOD with a GF Score™ of 67/100 and a GF Value™ of ฿1.53 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,656 Consumer Packaged Goods companies, DOD Biotech PCL ranks better than 51.39% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DOD Biotech PCL's enterprise value is ฿390.7 Mil.
DOD Biotech PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ฿43.2 Mil. Therefore, DOD Biotech PCL's EV-to-EBITDA for today is 9.05.
The historical rank and industry rank for DOD Biotech PCL's EV-to-EBITDA or its related term are showing as below:
BKK:DOD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.27 Med: 11.36 Max: 32.77
Current: 9.05
During the past 12 years, the highest EV-to-EBITDA of DOD Biotech PCL was 32.77. The lowest was -7.27. And the median was 11.36.
BKK:DOD's EV-to-EBITDA is ranked better than 51.39% of 1656
companies
in the Consumer Packaged Goods industry
Industry Median: 9.24
vs BKK:DOD: 9.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
DOD Biotech PCL (BKK:DOD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DOD Biotech PCL's PE Ratio (TTM) for today is calculated as:
DOD Biotech PCL's share price for today is ฿0.97.
DOD Biotech PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for DOD Biotech PCL's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, DOD Biotech PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DOD Biotech PCL EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DOD Biotech PCL's EV-to-EBITDA falls into.
DOD Biotech PCL's current Enterprise Value is ฿390.7 Mil.
DOD Biotech PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿43.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DOD Biotech PCL (BKK:DOD) has a EV-to-EBITDA of 9.05 as of Sep. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DOD Biotech PCL. This is 20% below median its historical median of 11.36. According to the industry distribution chart, DOD Biotech PCL ranks #805 out of 1656 companies in the Consumer Packaged Goods industry, placing it in the top 48.6%.
Is DOD Biotech PCL's EV-to-EBITDA too high?
DOD Biotech PCL's current EV-to-EBITDA of 9.05 is 20% below median its 10-year median of 11.36. The Consumer Packaged Goods industry median EV-to-EBITDA is 9.24. DOD Biotech PCL's value of 9.05 is 2.1% below this industry median. Based on the distribution chart, DOD Biotech PCL ranks #805 out of 1656 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, DOD Biotech PCL has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's EV-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, DOD Biotech PCL ranks #805 out of 1656 companies for EV-to-EBITDA. This puts DOD Biotech PCL in the upper half of its industry. The industry median EV-to-EBITDA is 9.24. DOD Biotech PCL's value of 9.05 is 2.1% below this benchmark. While the company's 10-year median is 11.36 vs. the industry median of 9.24, DOD Biotech PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.24, based on 1,656 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DOD Biotech PCL's current EV-to-EBITDA of 9.05 is 2.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DOD Biotech PCL. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DOD Biotech PCL's current EV-to-EBITDA is 9.05, which is 20% below median its own 10-year median of 11.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
Based on GuruFocus' analysis, DOD Biotech PCL (BKK:DOD) is currently considered Possible Value Trap. The stock's GF Value™ is ฿1.53, compared to a current price of ฿0.97 — trading 36.6% below its estimated fair value. The current EV-to-EBITDA is 9.05, which is 20% below median its 10-year median of 11.36 and 2.1% below the Consumer Packaged Goods industry median of 9.24. DOD Biotech PCL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD), the current EV-to-EBITDA is 9.05 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DOD Biotech PCL (BKK:DOD) Overvalued in 2026?
Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued.
The current stock price of ฿0.97 is trading 36.6% below its estimated GF Value™ of ฿1.53.
GuruFocus considers DOD Biotech PCL to be Possible Value Trap.
Key valuation signals for BKK:DOD:
EV-to-EBITDA: 9.05 (20% below median its 10-year median of 11.36)
GF Value™: ฿1.53 vs. price of ฿0.97 (36.6% below fair value)
Industry Position: 2.1% below the Consumer Packaged Goods median (#805 of 1656)
No single metric tells the full story. See the BKK:DOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
67GF Score
Get the complete analysis for BKK:DOD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:DOD has been successfully added to your 
